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Abstract
Background: Colorectal cancer (CRC) in patients aged under 55 years is on the rise, constituting approximately 10%
of cases. Our aim was to determine the survival and clinico-pathological details of young-onset CRC (yCRC), as well
as audit the referral rate to genetic services and thus establish the incidence of inherited cancer syndromes.
Methods: A retrospective case note review was conducted for patients aged under 55 years who were diagnosed
with CRC between 2005 and 2015 in the North East of Scotland. Cases were identified by pathology records and
data was obtained from patient notes. Analysis was performed using SPSS version 25 (IBM, New York, USA) to
produce Kaplan-Meier survival estimates, descriptive statistics and markers predictive for genetic referral.
Results: Data from 345 patients (age range 22–54 years) were identified. The one year, five year and overall survival
rates were found to be 89, 63 and 55%, respectively. Most patients (61%) presented with advanced disease. Of 201
patients that met criteria for genetic referral, only 93 (46%) were referred to genetic services. Microsatellite instability
(MSI) was identified in 14% of those referred.
Conclusion: Survival in yCRC was found to be better than that in later onset disease, despite higher rates of
advanced disease. Patients were under-referred to genetic services, where a significant proportion were found to
be MSI positive and investigated for Lynch syndrome.
Keywords: Young-onset colorectal cancer, Survival, Clinicopathological characteristics, Genetic referral, Microsatellite
instability
Background
Traditionally a disease of the elderly, colorectal cancer
(CRC) incidence in the young is steadily rising across
the globe [1, 2]. In contrast, the incidence of CRC in
older patients is seeing a progressive decrease in the
developed world, which is likely to be attributed to
population-based CRC screening [3–5]. CRC is the third
most common cancer worldwide, with approximately
10% of cases affecting patients aged under 55 years
[4, 6]. These younger patients often present with
more advanced disease and adverse pathological features
compared to their older counterparts [7]. This may have a
negative impact on their survival outcome [8].
Evidence regarding young-onset CRC (yCRC) patient
prognosis is conflicting. Some retrospective studies sug-
gest that younger patients have a poorer prognosis than
those with later-onset disease [8]. However, other studies
suggest their prognosis is better or equivalent to those
aged over 55 years [9].
Inherited predispositions to CRC are sometimes
responsible for causing the disease, especially within the
younger demographic [8]. These predispositions can be
divided into low-penetrance familial clusterings and
high-penetrance autosomal dominant cancer syndromes
[3]. The former carry a low associated risk to family
members and are assumed to have polygenic origin [3].
The latter are usually defined by germline mutation in
mismatch repair genes in the case of Lynch syndrome or
by a germline mutation in the adenomatous polyposis
coli (APC) gene for familial adenomatous polyposis
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(FAP) [3, 8]. Other causes of CRC are deemed sporadic
and are not thought to have a germline genetic predis-
position. The population prevalence of Lynch syndrome
has been estimated to be as high as 1:200 in some stud-
ies [10], with an associated lifetime risk of developing
CRC of 50–70% as well as an increased risk of endomet-
rial, ovarian and urothelial malignancies [11]. FAP ac-
counts for approximately 1% of all CRC cases and
carries a 100% lifetime risk of developing CRC [12].
Diagnosing Lynch syndrome or FAP – rather than spor-
adic CRC – has serious implications regarding a patient’s
management and family prevention [12, 10].
Given the relatively limited and conflicting data re-
garding this expanding subgroup of yCRC patients, the
primary aim of this study was to determine the survival
outcomes and clinico-pathological features of CRC pa-
tients aged under 55 years in the North East of Scotland.
During the time period of this study, the Scottish Inter-
collegiate Guidelines Network (SIGN) criteria were used
by the healthcare team in Aberdeen Royal Infirmary to
decide whether a patient should receive a genetic test
based on their age and family history [13, 14]. Consider-
ing the growing relevance of genetic results in yCRC pa-
tients’ management, the secondary aim of this study was
to determine the referral rate to genetic services and to
establish the incidence of MSI in this patient subgroup.
Methods
Patients were initially identified using pathology records
held at Aberdeen Royal Infirmary (ARI). The population
included patients from Aberdeen City, Aberdeenshire,
Orkney, Shetland and Moray. Inclusion criteria for the
study were a diagnosis of CRC between 2005 and 2015
and aged between 18 and 55 years old at the time of
diagnosis. Patients with unavailable or insufficient notes
and those who did not fit the pre-specified inclusion
criteria were excluded from the study. One patient was
lost to follow-up.
Following registration with and the approval of the
study by NHS Grampian Clinical Audit Unit, data were
extracted retrospectively from the NHS Grampian gen-
eral and genetic patient records, using the electronic
case record supplemented by paper files when required.
The general records are kept for the purpose of patient
care. The genetic case records are family based and
facilitate implementation of screening of the patient’s
relatives. De-identified data on patient characteristics
(age at the time of diagnosis, year of diagnosis, sex, pres-
entation and relevant past medical history); family
history (including genetic referral, referral source and
the outcome of referral); pathological details of tumour
(location, TNM staging, numerical staging, tumour dif-
ferentiation and genetic markers of tumour); treatment
approach; genetic care (referred to genetics services,
seen in clinic, undergone genetic testing and the associ-
ated result) and survival (disease recurrence, patient
deaths and time to death) were extracted. Disease recur-
rence was defined by the presence of disease post-
treatment on follow-up and imaging.
Data was analysed using SPSS statistics version 25
(IBM, New York, USA). Kaplan-Meier estimates were
used to evaluate survival and also compare survival out-
comes between age groups of CRC, presentation type,
chemotherapy agent, sex, tumour differentiation, numer-
ical staging, year of diagnosis and microsatellite instability
(MSI) status. The log rank test was used to evaluate
results, with p < 0.05 deemed as significant. Descriptive
statistics for age, sex, stage, site of cancer, co-morbidities
and treatment received were initially expressed as median
and interquartile range and percentages.
Genetic referral was assessed according to SIGN
guidelines in use when the cohort began (2005). Thus,
the prior guidelines from 2003 were used. The SIGN
guidelines currently used in clinical practice were up-
dated in 2011, although the differences between these
and the 2003 guidelines with regard to genetic referral
for CRC patients is negligible. To maintain consistency,
the 2003 guidelines were used throughout this study
despite being updated in 2011. This did not affect data
collection. They are summarised below:
1. All patients aged under 50 years require referral to
genetic services
2. All patients at a medium/high risk require referral
to genetics services – see Table 1
Results
Population
Between 03/01/2005 and 22/12/2015, 418 patients aged
under 55 years with a primary CRC were initially identi-
fied from the NHS Grampian pathology record. In total,
73 patients were excluded from the study due to no can-
cer found on further investigation, aged over 55 years at
diagnosis, diagnosed before 2005 or after 2015 or had
unavailable or insufficient notes (30 patients). Therefore,
the final number included in the study was 345. Age
ranged from 22 to 54, with a mean age of 47.7 years
(SD ± 6.1 years).
Survival
Death attributed to CRC occurred in one third of pa-
tients. Mean overall survival for CRC under 55 years was
96.1 months (95% confidence interval [CI], 89.2–102.9
months). In the univariate analysis, the following factors
were associated with longer survival: increased age, stage
I or II disease and presentation via screening. All
patients had at least 2 years follow-up and 80.6% of the
population had at least 5 years follow-up. The survival
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plots are shown in Fig. 1 and the corresponding survival
data is detailed in Table 2. Five year survival rates in
those aged less than 40 years was found to be worse
(57%) compared to those aged between 40 and 54 years
(68–62%).
Clinico-pathological characteristics
In patients with yCRC, disease presented symptomatic-
ally in 60.0%, as an emergency in 22.0% and incidentally
in 0.6% of patients. Only 30.0% of the patients aged 50–
55 years were identified through the bowel screening
programme. A small number of patients (4.0%) had a
past medical history of inflammatory bowel disease
(IBD). Similarly, 4.0% had had an unrelated previous
cancer such as testicular, vulval, breast or kidney cancer.
One patient had had a previous CRC. The distribution
of I-IV staging was 12, 26, 43 and 19%, respectively. In
patients aged under 40 years, 75.0% presented with ad-
vanced disease – i.e. stage III or IV disease. This is a
greater proportion compared to patients aged between
40 and 54 years where 59.3% presented with stage III or
IV disease. A majority of tumours (43.1%) were located
in the rectum and 3.5% of the cohort were identified to
have synchronous disease. Histologically, tumour differ-
entiation was reported as “well”, “medium” and “poor” in
1.2, 78.6 and 12.2% of patients, respectively. Patients
deemed incurable at diagnosis (10.7%) did not receive
surgical or endoscopic tumour resection due to late
stage disease. Adjuvant or neo-adjuvant chemotherapy
was administered to 81.3 and 34.1% had received radio-
therapy. Cancer recurrence occurred in 28.2% of patients
and 33.4% died of CRC. Epidemiological and clinico-
pathological characteristics of the patients by age are
displayed in Table 3.
Genetic referral
Family history (FH) was clearly documented in the gen-
eral case record notes of 185 (53.6%) patients. A positive
FH for CRC was reported in 91 (26.4%) patients, of
which 53 were first-degree. FH of associated Lynch syn-
drome tumours were also documented where possible;
endometrial cancer and breast cancer FH was positive in
10 (2.9%) and 25 (7.2%) patients, respectively. SIGN
guidelines (Table 1) were used to identify those requir-
ing genetic referral. All cases aged under 50 years
required referral – 172 patients (49.9%) – and those
also with a first-degree FH of Lynch-related tumours
– 88 patients (25.5%) – therefore qualified. Where
positive FH had been documented but details of age
or affected family member were unclear, cases were
categorised into referral required (4 cases). In total,
201 (58.3%) of the cohort required genetic referral. Of
these, 93 had such referral documented, however 108
patients who fulfilled the SIGN criteria to receive
genetic testing for MSI were not referred to genetic
services. An additional 18 patients were referred that
did not require a genetics referral based on age or
family history according to the SIGN 2003 guidelines.
However, 28 of those referred did not get tested.
Figure 2 demonstrates the referral of patients to gen-
etic services. Of the 83 tested, 12 patients (14.5%)
were identified to have Lynch syndrome and 3 pa-
tients (3.6%) identified to carry FAP.
As outlined in Fig. 2, a total of 111 patients (32.2% of
cohort) were referred to genetic services. A further 28
were also referred to genetics but not seen; possibly due
to patient choice, inability to attend appointments or pa-
tient death. After assessment by genetics services, family
risk was formally categorised. The low risk category in-
cluded 53 patients (47.7%), 43 patients (38.7%) were at
medium risk, and 15 patients (13.5%) were at high risk.
The risk was also analysed according to the original
referral required category, as shown in Table 4. Four of
the cases where family risk was considered high after
genetic testing were originally deemed unnecessary for
referral.
Discussion
The incidence of CRC is increasing in young patients
with seemingly few risk factors [9]. Currently, the notion
that younger age of onset is related to a poor prognosis
is controversial; survival data is rather ambiguous and
tumour characteristics are not consistently described for
this subgroup of yCRC patients [2, 8, 9]. Furthermore,
no such study has been completed in Scotland. By estab-
lishing survival and characterising clinico-pathological
features of this Scottish cohort, current knowledge and
practice relating to yCRC may improve on both a local
and international level.
Table 1 Summarised SIGN 2003 guidelines defining medium and high risk families
High Risk A least three family members affected by CRC, or at least
two affected by CRC and one affected by endometrial cancer.
One relative must be aged ≤50 years and one must be a
first degree relative.
Medium Risk One first degree relative with CRC ≤45 years
Gene carriers (HNPCC) Two first degree relatives affected (one aged < 55 years)
Untested first degree relatives of gene carriers At least two relatives with CRC or endometrial cancer
who are first degree relatives of each other
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In this retrospective study, survival in yCRC was found
to be better than that in later onset CRC despite higher
rates of advanced disease. Spanning an 11 year period up
to December 2015, follow-up and survival data from 345
CRC patients aged under 55 years was collected. Despite
a significant number of patients were diagnosed at late
stage disease, the cohort had a greater overall 5 year sur-
vival of 63%, compared to 59% - the latest 5 year survival
statistic for CRC across all age groups [15]. This may re-
flect the fitness and relative lack of co-morbidities of
these younger patients, making them better candidates
for surgery, chemotherapy and radiotherapy. We found
the 5 year survival of stage III and IV patients to be 67
and 18%, respectively. Across all age groups, 5 year sur-
vival in patients stage III disease is estimated at 63%, and
stage IV is 7% [15]. This suggests, contrary to popular
belief, that the young-onset cohort actually had similar
or better outcomes than colorectal cancer patients over-
all. This superior stage-specific survival is also reflected
in other multi-national studies [2, 4, 9, 12]. However, in
contrast, these studies did not find survival outcomes to
be greater even when unadjusted to stage. This is likely
to be because these studies tended to focus on patient





Fig. 1 Kaplan-Meier Survival Charts
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under 55 years. When our results are adjusted to age-
specific survival, those less than 40 years of age were also
found to have a poorer prognosis. Interestingly, one
study consistent with this result by Ballester et al. also
found that - despite an overall better prognosis - yCRC
patients had a higher incidence of recurrence and devel-
opment of metastasis than later-onset disease. In this
study, tumour recurrence occurred in 22.6% of patients.
In a Korean study considering CRC across all ages,
recurrent disease was found to occur in 18.3% [16].
Although inconclusive, this is potentially an area for
further investigation to determine why yCRC patients
may have a higher incidence of tumour recurrence.
This study also characterised the cohort in terms of
clinicopathological features, which found locally ad-
vanced rectosigmoid disease to be typical of yCRC.
Tumours were commonly located in the left side of the
bowel, with a greater proportion of tumours (42.6%) oc-
curring in the rectum – concurring with previous litera-
ture describing young-onset disease [7]. Although our
cohort is relatively small, it includes all the patients in a
geographical area, including both urban & rural popula-
tions. Over 60% of patients presented with late stage (III
or IV) disease. According to cancer research statistics, in
Scotland approximately 23% of CRC patients present
with stage IV disease and 25% with stage III disease [17].
In this cohort, perhaps surprisingly, fewer patients pre-
sented with stage IV disease (18%), although there were
nearly 70% more patients (42%) diagnosed initially with
stage III disease compared to the national incidence
across all ages. Advanced disease prior to diagnosis may
be explained by delays in patient presentation and diag-
nosis due to the relative rarity of the condition in com-
parison to the older population, as well as a lack of
screening. In Scotland, population screening does not
begin until the age of 50. In contrast with previous stud-
ies investigating yCRC [12, 18], incidence of poorly dif-
ferentiated – or high-grade – histology was not found to
be overrepresented in our patient group. An Australian
study concurs with this finding, putting this discrepancy
down to the subjective nature of determining tumour
grade across the world [2].
Of those referred to genetic services, a significant pro-
portion (18%) were found to be MSI positive. FH was
often not documented sufficiently or, in some cases, not
at all. FH is a major determining factor for referral to
genetic services given the autosomal dominant inherit-
ance pattern of Lynch syndrome. SIGN 2003 guidelines
state that a ‘three generation family history should be
taken from all patients with colorectal cancer’ [14]. This
was not adhered to and hindered the assessment of
whether a patient required genetic referral, both for the
purposes of this audit and in clinical practice. The audit
found that only 46% of patients categorised as requiring
referral had indeed been referred to genetics as part of
their cancer management. However, given the poor FH
records, there were potentially more unidentified pa-
tients who required referral. This falls far below the
audit standard; 54% of the unseen patients requiring re-
ferral potentially have an unidentified underlying genetic
risk implicating not only their future health, but also
their families. Failure to identify these high or medium
risk families may have grave repercussions on the mor-
tality and morbidity of these patients, as having know-
ledge of this risk allows access to the appropriate
screening and counselling. Interestingly, four of the 18
patients categorised as not requiring referral (therefore
were aged over 50 years and had no known FH of CRC
documented) who were seen and tested by genetics ser-
vices were actually found to be carriers of Lynch syn-
drome, and as such fell into the high risk category.
Perhaps insufficient FH documentation is responsible for
these unexpected results. The findings of this study are
in accordance with the published literature. A similar
multi-centred English audit was conducted in 2011. Al-
though using a different referral criteria in line with their
own clinical practice, findings showed that the referral
rate ranged from between only 35–55% [10]. The find-
ings have also been echoed internationally; a Dutch
study found that documentation of family history was
sub-optimal, being correctly documented in only 16% of
cases. 34% of patients with a complete FH recorded were
referred genetics services [19]. In 2009, an Australian






Overall 96.1 ± 3.5 63
Age group 0.005
< 30 46.9 ± 12.1 57
30–39 62.1 ± 7.0 57
40–49 87.3 ± 4.5 68
50–54 96.2 ± 4.8 62
Numerical Stage < 0.001
I 104.0 ± 5.0 94
II 102.4 ± 3.9 82
III 86.8 ± 4.0 67
IV 32.2 ± 4.6 18
Sex 0.212
Male 99.3 ± 4.8 64
Female 81.1 ± 4.1 61
Presentation Type < 0.001
Elective 90.1 ± 3.7 69
Emergency 61.0 ± 6.3 39
Screening 100.4 ± 5.1 82
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study showed even poorer outcomes with only 54% of
patients having FH documented, and only 12% of
patients being referred for formal genetic testing [20].
Another 2012 study from Australia claimed only 38% of
CRC patients were asked about their family by a health
care provider [21]. The reason behind these findings
may have been due to documentation errors; perhaps if
a negative FH was found on enquiry, no FH documenta-
tion was made at all. However, even if this were the case,
opportunities for patient referral to genetic services are
almost certain to have been missed.
Despite meticulous data collection from an 11 year
time period with at least 2 years survival follow-up, this
study does have its limitations. Firstly, the cohort size of
Table 3 Epidemiological and clinicopathological characteristics of patients by age
Characteristic Age (n/%) Total
≤ 29 30–39 40–49 50–54
Count 6 (1.7%) 34 (9.9%) 132 (38.2%) 173 (50.1%) 345 (100%)
Sex
Male 3 (0.9%) 19 (5.5%) 69 (20.0%) 91 (26.0%) 182 (52.8%)
Female 3 (0.9%) 15 (4.3%) 63 (18.0%) 82 (23.8%) 163 (47.2%)
Presentation
Elective 2 (0.6%) 21 (6.1%) 95 (27.5%) 89 (25.8%) 207 (60.0%)
Emergency 3 (0.9%) 12 (3.5%) 33 (9.6%) 28 (8.1%) 76 (22.0%)
Screening 0 0 1 (0.3%) 52 (15.1%) 53 (15.4%)
Incidental 0 0 1 (0.3%) 1 (0.3%) 2 (0.6%)
Unknown 1 (0.3%) 1 (0.3%) 2 (0.6%) 3 (0.9%) 7 (2.0%)
Past Medical History
IBD 0 4 (1.2%) 3 (0.9%) 7 (2.0%) 14 (4.1%)
Previous cancer 0 1 (0.3%) 4 (1.2%) 9 (2.6%) 14 (4.1%)
Alcoholism 0 2 (0.6%) 12 (3.5%) 14 (4.1%) 28 (8.1%)
Numerical Stage
I 0 2 (0.6%) 12 (3.5%) 27 (7.8%) 41 (11.9%)
II 2 (0.6%) 5 (14.5%) 37 (10.7%) 46 (13.3%) 90 (26.1%)
III 3 (0.9%) 16 (4.6%) 59 (17.1%) 68 (19.7%) 146 (42.3%)
IV 1 (0.3%) 10 (2.9%) 23 (6.7%) 31 (9.0%) 65 (18.8%)
Tumour Location
Right 1 (0.3%) 6 (1.7%) 18 (5.2%) 35 (10.1%) 60 (17.4%)
Left 3 (0.9%) 12 (3.5%) 53 (15.4%) 61 (17.7%) 129 (37.4%)
Rectal 2 (0.6%) 16 (4.6%) 55 (15.9%) 74 (21.4%) 147 (42.6%)
Transverse 0 0 3 (0.9%) 2 (0.6%) 5 (1.4%)
Tumour Differentiation
Well 0 0 2 (0.6%) 3 (0.9%) 4 (1.2%)
Medium 5 (1.4%) 23 (6.7%) 106 (30.7%) 137 (39.7%) 271 (78.6%)
Poor 1 (0.3%) 8 (2.3%) 17 (4.9%) 16 (4.6%) 42 (12.2%)
Undocumented 0 3 (0.9%) 8 (2.3%) 17 (4.9%) 28 (8.1%)
Management
Surgical 5 (1.4%) 27 (7.8%) 117 (33.9%) 155 (44.9%) 304 (88.1%)
Palliative 1 (0.3%) 6 (1.7%) 14 (4.1%) 16 (4.6%) 37 (10.7%)
Chemotherapy Received 5 (1.4%) 31 (9.0%) 110 (31.9%) 133 (38.6%) 279 (80.9%)
Radiotherapy Received 0 14 (4.1%) 42 (12.2%) 61 (17.7%) 117 (33.9%)
Tumour Recurrence 0 5 (1.4%) 40 (11.6%) 33 (9.6%) 78 (22.6%)
Patient Deceased 3 (0.9%) 14 (4.1%) 42 (12.2%) 55 (15.9%) 114 (33.0%)
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345 patients is relatively small. When considering the
division of patients into further lesser subgroups (for
example, by age), this has obtained results often with a
low power. Only 80.6% of patients had at least 5 years of
follow-up at data collection. When the 67 individuals
diagnosed after August 2013 (since data was collected in
August 2018) who did not have 5 years follow-up are
excluded, the values in Table 2 remain consistent. The
data collection process introduced a degree of bias since
most patient information was collected from oncology
notes and other hospital notes including ward clerking.
Pathology reports were less often accessed as this was
more time consuming. Where patient notes were
deemed unavailable, it was likely that these patients did
not receive any oncology treatment due to early stage
disease requiring only surgical intervention. Two separ-
ate researchers collated the data; one gathered data from
2005 to 2009 and the other gathered data from 2010 to
2015. Despite efforts to ensure data collection was iden-
tical both times, there may have been minor discrepan-
cies in methods, recording and benchmarks. As the
SIGN (2003) guidelines were in use during 2005–2009,
they were also used as the guideline standards for the
2010–2015 cohort accepting that the SIGN guidelines
were updated in December 2011. These new guidelines
aimed to further improve the uptake of genetic referrals,
although differences between the 2003 and 2011 stan-
dards were negligible regarding young-onset CRC and
59 patients based on age (<50 
years) and family history
29 patients based on family history 
alone
113 patients based on age alone 
(<50 years)
345 patients
144 patients did not require a 
genetic referral based on age 
>50 years and family history
111 patients referred to 
genetics services for testing
201 patients required a 
genetic referral
93 patients were 
referred
18 patients were 
referred
108 patients requiring 
referral were not referred 
to genetics services
15 patients were found to have an 
inherited MSI mutation; 12 Lynch 
Syndrome and 3 FAP
68 patients had no 
identifiable genetic 
abnormality




Fig. 2 Flow-chart of Patients Referred and Tested by Genetic Services
Table 4 Referral category against risk
Categorised Risk (n)
Unable to determine Low Medium High Total (n)
Referral required 28 42 12 11 93
Referral not required 0 11 3 4 18
Total 28 53 15 15 111
Actual family risk of CRC according to characterisation of requirement to genetic referral
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did not affect this study [13, 14]. Routine assessment for
Lynch syndrome is now the standard assessment of a
tumour, and patient referral is no longer required. Re-
audit will allow ascertainment in change of policy. ARI’s
pathology dataset was updated in July 2014 to include
immunohistochemistry (IHC) analysis looking at micro-
satellite mismatch proficiency on all specimens from
patients aged less than 50 years. Since then, in 2015, all
patients having a resection for a diagnosis of colorectal
cancer in the North East of Scotland have had the
KRAS, BRAF and MSI status assessed on their surgical
specimen. As patients with rectal cancer may require
pre-operative therapy, immunohistochemistry (IHC)
analysis for microsatellite proficiency is carried out on
biopsy specimens, as this may influence therapeutic
options. Therefore, significant improvements have been
made with regard to identification of hereditary cancer
syndromes.
Conclusion
In this study, overall survival in the under 55 s was
found to surpass that of CRC across all ages. This is im-
portant to discuss with yCRC patients, as perceptions in
the general population reckon that young adult patients
with cancer have an inferior outcome compared to pa-
tients with later-onset disease. However, patients aged
under 40 years were found to have more advanced dis-
ease and a slightly poorer prognosis than those aged
over 40 years. Since the Scottish Bowel Cancer Screening
Programme will not detect cases in patients under 50
years, healthcare professionals should be especially vigi-
lant. A significant lack of appropriate patient referral to
genetic services was found from 2005 to 2015. Thus, op-
portunities for identification of potential hereditary can-
cer syndromes and screening are likely to have been
missed in a significant high-risk patient group. Although
many patients did not receive genetic testing, 18% of
those who were tested were found to carry Lynch syn-
drome or FAP.
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